Adenovirus-mediated Expression of Antisense Urokinase Plasminogen Activator Receptor and Antisense Cathepsin B Inhibits Tumor Growth, Invasion, and Angiogenesis in Gliomas
Overview
Authors
Affiliations
We have shown previously that urokinase plasminogen activator receptor (uPAR) and cathepsin B are overexpressed during glioma progression, particularly at the leading edge of the tumor. In the present study, we simultaneously down-regulated uPAR and cathepsin B in SNB19 glioma cell monolayer or SNB19 spheroids using an adenoviral vector carrying antisense uPAR and antisense cathepsin B and a combination of these genes as determined by Western blot analysis. The Ad-uPAR-Cath B-infected cells revealed a marked reduction in tumor growth and invasiveness as compared with the parental and vector controls. In vitro and in vivo angiogenic assays demonstrated inhibition of capillary-like structure formation and microvessel formation after Ad-uPAR-Cath B infection of SNB19 cells when compared with Ad-cytomegalovirus (CMV)-infected or mock-infected controls. Furthermore, using a near infrared fluorescence probe, in vivo imaging for cathepsin B indicated low/undetectable levels of fluorescence after injection of the Ad-uPAR-Cath B construct into pre-established s.c. tumors as compared with Ad-CMV-treated and untreated tumors. The effect with bicistronic construct (Ad-uPAR-Cath B) was much higher than with single (Ad-uPAR/Ad-Cath B) constructs. These results indicate that the down-regulation of cathepsin B and uPAR plays a significant role in inhibiting tumor growth, invasion, and angiogenesis. Hence, the targeting of these two proteases may be a potential therapy for brain tumors and other cancers.
Norton E, Whaley L, Jones V, Brooks M, Russo M, Morderer D Sci Adv. 2024; 10(32):eadn1607.
PMID: 39110807 PMC: 11305394. DOI: 10.1126/sciadv.adn1607.
Smart Delivery Systems Responsive to Cathepsin B Activity for Cancer Treatment.
Egorova V, Kolesova E, Lopus M, Yan N, Parodi A, Zamyatnin Jr A Pharmaceutics. 2023; 15(7).
PMID: 37514035 PMC: 10386206. DOI: 10.3390/pharmaceutics15071848.
Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.
Zhai B, Tian H, Sun J, Zou J, Zhang X, Cheng J J Transl Med. 2022; 20(1):135.
PMID: 35303878 PMC: 8932206. DOI: 10.1186/s12967-022-03329-3.
Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives.
Seker-Polat F, Pinarbasi Degirmenci N, Solaroglu I, Bagci-Onder T Cancers (Basel). 2022; 14(2).
PMID: 35053605 PMC: 8773542. DOI: 10.3390/cancers14020443.
Cysteine cathepsins B, X and K expression in peri-arteriolar glioblastoma stem cell niches.
Breznik B, Stokin C, Kos J, Khurshed M, Hira V, Bosnjak R J Mol Histol. 2018; 49(5):481-497.
PMID: 30046941 PMC: 6182580. DOI: 10.1007/s10735-018-9787-y.